244 related articles for article (PubMed ID: 10215648)
1. SR146131: a new potent, orally active, and selective nonpeptide cholecystokinin subtype 1 receptor agonist. I. In vitro studies.
Bignon E; Bachy A; Boigegrain R; Brodin R; Cottineau M; Gully D; Herbert JM; Keane P; Labie C; Molimard JC; Olliero D; Oury-Donat F; Petereau C; Prabonnaud V; Rockstroh MP; Schaeffer P; Servant O; Thurneyssen O; Soubrié P; Pascal M; Maffrand JP; Le Fur G
J Pharmacol Exp Ther; 1999 May; 289(2):742-51. PubMed ID: 10215648
[TBL] [Abstract][Full Text] [Related]
2. SR146131: a new potent, orally active, and selective nonpeptide cholecystokinin subtype 1 receptor agonist. II. In vivo pharmacological characterization.
Bignon E; Alonso R; Arnone M; Boigegrain R; Brodin R; Gueudet C; Héaulme M; Keane P; Landi M; Molimard JC; Olliero D; Poncelet M; Seban E; Simiand J; Soubrié P; Pascal M; Maffrand JP; Le Fur G
J Pharmacol Exp Ther; 1999 May; 289(2):752-61. PubMed ID: 10215649
[TBL] [Abstract][Full Text] [Related]
3. Characterisation of the effects of SR146131, a novel non-peptide CCK(1) receptor agonist, on IMR-32 human neuroblastoma cells.
Schaeffer P; Nestor AL; Prabonnaud V; Bachy A; Laplace MC; Keane PE; Bignon E; Herbert JM
Eur J Pharmacol; 2000 Jun; 397(2-3):303-10. PubMed ID: 10844128
[TBL] [Abstract][Full Text] [Related]
4. Protein kinase C-mediated inhibition of transmembrane signalling through CCK(A) and CCK(B) receptors.
Smeets RL; Fouraux MA; van Emst-de Vries SE; De Pont JJ; Willems PH
Br J Pharmacol; 1998 Mar; 123(6):1189-97. PubMed ID: 9559904
[TBL] [Abstract][Full Text] [Related]
5. Mutational analysis of the potential phosphorylation sites for protein kinase C on the CCK(A) receptor.
Smeets RL; Fouraux MA; Pouwels W; van Emst-de Vries SE; Ronken E; De Pont JJ; Willems PH
Br J Pharmacol; 1998 Jul; 124(5):935-45. PubMed ID: 9692779
[TBL] [Abstract][Full Text] [Related]
6. SR146131, a cholecystokinin-A receptor agonist, antagonizes prepulse inhibition deficits produced by dizocilpine and DOI.
Shilling PD; Feifel D
Psychopharmacology (Berl); 2002 Nov; 164(3):285-93. PubMed ID: 12424552
[TBL] [Abstract][Full Text] [Related]
7. Structure-based design of new constrained cyclic agonists of the cholecystokinin CCK-B receptor.
Blommaert AG; Dhôtel H; Ducos B; Durieux C; Goudreau N; Bado A; Garbay C; Roques BP
J Med Chem; 1997 Feb; 40(5):647-58. PubMed ID: 9057851
[TBL] [Abstract][Full Text] [Related]
8. Full and partial agonist activity of C-terminal cholecystokinin peptides at the cloned human CCK-A receptor expressed in Chinese hamster ovary cells.
Dunlop J; Zhang Y; Evans N
Peptides; 1997; 18(6):865-8. PubMed ID: 9285936
[TBL] [Abstract][Full Text] [Related]
9. Concerted action of cytosolic Ca2+ and protein kinase C in receptor-mediated phospholipase D activation in Chinese hamster ovary cells expressing the cholecystokinin-A receptor.
Bosch RR; Smeets RL; Sleutels F; Patel AM; Emst-de Vries SE; Joep J; de Pont HH; Willems PH
Biochem J; 1999 Jan; 337 ( Pt 2)(Pt 2):263-8. PubMed ID: 9882623
[TBL] [Abstract][Full Text] [Related]
10. CCK1 and 2 receptors are expressed in immortalized rat brain neuroblasts: intracellular signals after cholecystokinin stimulation.
Langmesser S; Cerezo-Guisado MI; Lorenzo MJ; Garcia-Marin LJ; Bragado MJ
J Cell Biochem; 2007 Mar; 100(4):851-64. PubMed ID: 17226751
[TBL] [Abstract][Full Text] [Related]
11. CCK2 receptors mediate inhibitory effects of cholecystokinin on the motor activity of guinea-pig distal colon.
Fornai M; Colucci R; Antonioli L; Baschiera F; Ghisu N; Tuccori M; Gori G; Blandizzi C; Del Tacca M
Eur J Pharmacol; 2007 Feb; 557(2-3):212-20. PubMed ID: 17208221
[TBL] [Abstract][Full Text] [Related]
12. CCK(B)/gastrin receptor mediates synergistic stimulation of DNA synthesis and cyclin D1, D3, and E expression in Swiss 3T3 cells.
Zhukova E; Sinnett-Smith J; Wong H; Chiu T; Rozengurt E
J Cell Physiol; 2001 Dec; 189(3):291-305. PubMed ID: 11748587
[TBL] [Abstract][Full Text] [Related]
13. Discovery of 1,5-benzodiazepines with peripheral cholecystokinin (CCK-A) receptor agonist activity (II): Optimization of the C3 amino substituent.
Hirst GC; Aquino C; Birkemo L; Croom DK; Dezube M; Dougherty RW; Ervin GN; Grizzle MK; Henke B; James MK; Johnson MF; Momtahen T; Queen KL; Sherrill RG; Szewczyk J; Willson TM; Sugg EE
J Med Chem; 1996 Dec; 39(26):5236-45. PubMed ID: 8978852
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological characterization of rebamipide: its cholecystokinin CCK1 receptor binding profile and effects on Ca2+ mobilization and amylase release in rat pancreatic acinar cells.
Moon SJ; An JM; Kim J; Lee SI; Ahn W; Kim KH; Seo JT
Eur J Pharmacol; 2004 Nov; 505(1-3):61-6. PubMed ID: 15556137
[TBL] [Abstract][Full Text] [Related]
15. Protein hydrolysates induce CCK release from enteroendocrine cells and act as partial agonists of the CCK1 receptor.
Foltz M; Ansems P; Schwarz J; Tasker MC; Lourbakos A; Gerhardt CC
J Agric Food Chem; 2008 Feb; 56(3):837-43. PubMed ID: 18211011
[TBL] [Abstract][Full Text] [Related]
16. Arginine 197 of the cholecystokinin-A receptor binding site interacts with the sulfate of the peptide agonist cholecystokinin.
Gigoux V; Maigret B; Escrieut C; Silvente-Poirot S; Bouisson M; Fehrentz JA; Moroder L; Gully D; Martinez J; Vaysse N; Fourmy AD
Protein Sci; 1999 Nov; 8(11):2347-54. PubMed ID: 10595537
[TBL] [Abstract][Full Text] [Related]
17. Optimization of 3-(1H-indazol-3-ylmethyl)-1,5-benzodiazepines as potent, orally active CCK-A agonists.
Henke BR; Aquino CJ; Birkemo LS; Croom DK; Dougherty RW; Ervin GN; Grizzle MK; Hirst GC; James MK; Johnson MF; Queen KL; Sherrill RG; Sugg EE; Suh EM; Szewczyk JW; Unwalla RJ; Yingling J; Willson TM
J Med Chem; 1997 Aug; 40(17):2706-25. PubMed ID: 9276016
[TBL] [Abstract][Full Text] [Related]
18. Type-A cholecystokinin receptors in CHP212 neuroblastoma cells: evidence for association with G protein and activation of phosphoinositide hydrolysis.
Barrett RW; Steffey ME; Wolfram CA
Mol Pharmacol; 1989 Apr; 35(4):394-400. PubMed ID: 2539554
[TBL] [Abstract][Full Text] [Related]
19. Proliferative effects of cholecystokinin in GH3 pituitary cells mediated by CCK2 receptors and potentiated by insulin.
Smith AJ; McKernan RM
Br J Pharmacol; 1999 Jan; 126(1):79-86. PubMed ID: 10051123
[TBL] [Abstract][Full Text] [Related]
20. Selective CCK-A but not CCK-B receptor antagonists inhibit HT-29 cell proliferation: synergism with pharmacological levels of melatonin.
González-Puga C; García-Navarro A; Escames G; León J; López-Cantarero M; Ros E; Acuña-Castroviejo D
J Pineal Res; 2005 Oct; 39(3):243-50. PubMed ID: 16150104
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
